Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Glaukos Corporation Common Stock (NY:GKOS)

94.30 +4.34 (+4.82%)
Streaming Delayed Price Updated: 1:20 PM EDT, May 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Glaukos Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
Glaukos Announces Participation in Wells Fargo Healthcare Conference
From Glaukos Corporation
Via Business Wire
Glaukos Announces Second Quarter 2023 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos's Earnings Outlook
Via Benzinga
Analyst Ratings for Glaukos
Via Benzinga
Glaukos Poised To Surpass Expectations And Raise Outlook In Q2 FY23, Fueled By iStent And iAccess Launches: Analyst
Needham expects Glaukos Corp (NYSE: GKOS) to surpass expectations and raise outlook in Q2 FY23, fueled by rebounding iStent inject volumes post-2022 reimbursement-driven declines. An additional upside... 
Via Benzinga
Where Glaukos Stands With Analysts
Via Benzinga
Stifel Maintains Buy Rating for Glaukos: Here's What You Need To Know
Via Benzinga
8 Analysts Have This to Say About Glaukos
Via Benzinga
Analyst Expectations for Glaukos's Future
Via Benzinga
Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.
From Glaukos Corporation
Via Business Wire
These 2 Soaring Stocks Finished the Week Strong
Wall Street coasted into the close on Friday but still had a good week. 
Via The Motley Fool
UnitedHealth, Elanco Animal Health And Other Big Stocks Moving Higher On Friday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Friday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Glaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023
From Glaukos Corporation
Via Business Wire
Glaukos: Q1 Earnings Insights
Via Benzinga
Expert Ratings for Glaukos
Via Benzinga
Earnings Preview For Glaukos
Via Benzinga
Glaukos Poised for $1B in Sales by 2030: Piper Sandler Predicts With Stock Upgrade
Piper Sandler has upgraded Glaukos Corporation (NYSE: GKOS) to Overweight from a Neutral ra 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 7, 2023
Via Benzinga
Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)
From Glaukos Corporation
Via Business Wire
Glaukos Announces Participation in the William Blair Growth Stock Conference
From Glaukos Corporation
Via Business Wire
Tyson Foods, PayPal And 3 Stocks To Watch Heading Into Monday
With US stock futures trading slightly lower this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
Glaukos Announces FDA Acceptance of NDA Submission for iDose TR
From Glaukos Corporation
Via Business Wire
Glaukos Announces First Quarter 2023 Financial Results
From Glaukos Corporation
Via Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting
From Glaukos Corporation
Via Business Wire
Glaukos Announces the Release of its 2022 Sustainability Report
From Glaukos Corporation
Via Business Wire
Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3
From Glaukos Corporation
Via Business Wire
Glaucoma Is The Second Leading Cause Of Blindness Globally – Skye Bioscience Appears To Be Making Rapid Progress In The Development Of Their Candidate To Treat It
Biomed company Skye Bioscience (OTCQB: SKYE) has seen positive results in its clinical research so far and is preparing for the next stage in the development of its therapy for eye disease.  
Via Benzinga
Glaukos Submits New Drug Application to U.S. FDA for iDose TR
From Glaukos Corporation
Via Business Wire
NVIDIA To Rally Over 20%? Here Are 10 Other Analyst Forecasts For Thursday
Goldman Sachs boosted the price target for Vir Biotechnology, Inc. (NASDAQ: VIR) from $41 to $53. Goldman Sachs analyst Paul Choi maintained a Buy rating on the stock. Vir Biotechnology shares rose... 
Via Benzinga
Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results
From Glaukos Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.